Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
NCT ID: NCT05171530
Last Updated: 2021-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
19 participants
INTERVENTIONAL
2022-01-05
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will adopt the "3+3" dose escalation design. All patients received a standard dose of chemotherapy: paclitaxel 135mg/m2 every 3 weeks or docetaxel 75mg/m2 every 3 weeks. Lenvatinib is exploring four doses of 4mg, 8mg, 12mg, and 16mg, orally once a day every 3 weeks. In the first cycle, lenvatinib was administered 5 days before chemotherapy，once a day. Chemotherapy lasts up to 6 cycles, and lenvatinib continues to be administered until the disease progresses, intolerable side effects, or death.
In order to avoid the possible ineffectiveness caused by the patient being exposed to low doses, the initial dose of 4 mg was enrolled in 1 patient. If there is no obvious dose-limiting toxicity (DLT) after the first dose, the dose escalation adopts a "3+3" method from the 8mg dose: if none of the 3 subjects in the previous dose group has a DLT within 21 days, the next dose study will be carried out; if one subject in the group has DLT occurs, then 3 additional subjects should be added to the dose group; if the 3 subjects have 1 or more DLTs, the trial terminated and the previous dose was regarded as the maximum tolerated dose (MTD).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lenvatinib with taxane drugs treatment for advanced gastric cancer
Experimental: Lenvatinib plus taxane drugs The subjects in this arm will receive a Lenvatinib combined with single-agent taxanes therapy. A standard dose of chemotherapy: paclitaxel 135mg/m2 every 3 weeks or docetaxel 75mg/m2 every 3 weeks will be administrated. Lenvatinib is exploring four doses of 4mg, 8mg, 12mg, and 16mg, orally once a day every 3 weeks. In the first cycle, lenvatinib was administered 5 days before chemotherapy，once a day. Chemotherapy lasts up to 6 cycles, and lenvatinib continues to be administered until the disease progresses, intolerable side effects, or death.
Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and there is no obvious DLT within 21 days before the next subject can be treated.
Interventions:
* Drug: Paclitaxel or Docetaxel
* Drug: Lenvatinib
Lenvatinib plus taxane drugs
* Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX
* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA
* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lenvatinib plus taxane drugs
* Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX
* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA
* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Advanced gastric cancer diagnosed by histopathological or cytological examination, no uncontrollable pleural and ascites;.
3. Age no less than 18 years.
4. Life expectancy greater than 3 months.
5. According to the RECIST (Response Evaluation Criteria in Solid Tumors) standard, there must be measurable lesions.
6. Failed at the standard first-line therapy, microsatellite stable (MSS) or no mismatch repair missing(PMMR), HER2 negative.
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 .
8. Adequate liver/bone marrow function.
9. Female subjects must meet the following conditions: infertility or fertility and use high-efficiency contraceptive measures.
10. Male subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for 3 months following the last dose of the study cell infusion. Moreover, all men are absolutely prohibited from donating sperm within 1 year after receiving the last study treatment infusion.
Exclusion Criteria
2. Pregnant or breast-feeding female, or not willing to take contraception measures during study.
3. Uncontrolled brain metastasis or mental illness.
4. Suffered from other uncured malignant tumors within the past 3 years or at the same time.
5. A history of active gastrointestinal bleeding within 3 months, incomplete obstruction or complete intestinal obstruction.
6. Uncontrollable high blood pressure are not suitable for enroll into the study.
7. Other uncontrolled diseases may cause abnormal death of the patient.
8. Untolerable liver/bone marrow function.
9. Factors that affect the administration of oral drugs (dysphagia, chronic diarrhea, complete intestinal obstruction, etc.
10. Previously allergic to the ingredients of the medicine in regimen.
11. Can't be followed up or obey protocol.
12. The investigator believes that it is not appropriate to participate in the trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yan Shi
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Shi
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yan Shi
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LOGIC
Identifier Type: -
Identifier Source: org_study_id